ICID 2020

20-23 February 2020
Kuala Lumpur, Malaysia

  • DNDi is a collaborating organization

3rd World Conference on Access to Medical Products

19-21 November 2019
New Delhi, India

  • Suman Rijal, Director of DNDi Regional Office – session on medical products for end game for HIV, TB, and malaria
  • Michelle Childs, Head of Policy Advocacy – session on antimicrobial resistance

GARDP set up as independent legal entity

Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

DNDi reçoit le Prix 2017 de l’Innovation à Genève pour récompenser son action en faveur des populations les plus négligées

A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).

More than EUR 56 million raised to fund initiative to fight antibiotic resistance

[Berlin – 4 September 2017]
Germany hosts pledging event for GARDP, a new initiative to develop new antibiotic treatments
Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research.
[Deutsch]

Gröhe: „Wichtiger Schritt im Kampf gegen Antibiotika-Resistenzen“

[Berlin – 4 September 2017]
Mehr als 56 Millionen Euro für die Erforschung und Entwicklung neuer Antibiotika zugesagt
Mit 56,5 Millionen Euro wollen die Bundesrepublik Deutschland und weitere internationale Geldgeber die Erforschung und Entwicklung neuer Antibiotika vorantreiben. Die Mittel wurden der Globalen Partnerschaft für Antibiotika-Forschung und Entwicklung – GARDP (Global Antibiotic Research and Development Partnership) – im Rahmen einer Veranstaltung auf Einladung von Bundesgesundheitsminister Hermann Gröhe und Georg Schütte, Staatssekretär im Bundesministerium für Bildung und Forschung, in Berlin zugesagt.
[English]

DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years

[Geneva – 8 August 2017]
The Drugs for Neglected Diseases initiative (DNDi) announced today the appointment of Dr Marie-Paule Kieny as the new Chair of the Board of Directors. Dr Kieny, a former World Health Organization (WHO) Assistant Director-General, brings more than four decades of experience in public health and innovation to DNDi’s work in developing new treatments for neglected patients. Until July 2017, Dr Kieny led WHO’s Health Systems and Innovation cluster. During her career at WHO, she also led its Innovation, Information, Evidence and Research cluster, directed the WHO Initiative for Vaccine Research and led the organization’s activities on Ebola and Zika research, as well as the preparation of an R&D Blueprint to accelerate global preparedness for future pandemics. Before joining WHO in 2001, Dr Kieny was Director of Research at the Institute of Virology, Institut national de la Santé et de la Recherche médicale in Paris (INSERM) and Assistant Scientific Director of French biopharmaceutical company Transgene SA.